-
Domestic pharmaceutical companies are enthusiastic about the research and development of new chemical drugs, and the results are gradually emerging
Time of Update: 2022-09-14
Analysts believe that it is obvious from the number of registrations that the enthusiasm of domestic pharmaceutical companies for the research and development of new chemical drugs is continuing to rise.
-
Mergers and acquisitions in the biomedical industry have become a trend! In the past three years, more than 900 cases have occurred, and the total amount of mergers and acquisitions has reached 100 billion
Time of Update: 2022-09-14
In addition, from the statistics of the past three years, more than 900 mergers and acquisitions in the biomedical industry have occurred, involving an amount of 171 billion yuan.
-
The standardized development of the Traditional Chinese Medicine Tablets industry is further! The total pass rate of sampling inspection reaches 98%
Time of Update: 2022-09-14
In order to purify the Chinese herbal medicine market, in February 2020, the State Food and Drug Administration issued the "Special Rectification Work Plan for Chinese Medicine Tablets", which put forward the overall objectives and work points for the special rectification of Chinese medicine tablets nationwide, and then successively introduced local special rectification work plans for Chinese medicine tablets, strengthened the frequency of sampling inspections, named and exposed unqualified pharmaceutical enterprises, and further standardized the development of the industry.
-
Under the continuous investment in research and development, the income of many pharmaceutical companies in innovative drugs has reached a new high!
Time of Update: 2022-09-14
【Pharmaceutical Network Industry News】At present, the 2022 interim report of listed pharmaceutical companies has been disclosed one after another, and it can be seen from the reports of many pharmaceutical companies that through continuous investment in research and development, a number of pharmaceutical companies have achieved great results in innovative drugs, driving high revenue growth in the first half of the year.
-
The continuous growth of the income of the Chinese medicine industry has promoted the acceleration of strategic adjustment and upgrading of Chinese medicine enterprises
Time of Update: 2022-09-14
For example, among the listed Chinese medicine companies that disclosed their 2021 annual reports, more than half of the R&D investment of enterprises achieved year-on-year growth.
For example, among the listed Chinese medicine companies that disclosed their 2021 annual reports, more than half of the R&D investment of enterprises achieved year-on-year growth.
-
DPP-4 inhibitors have gradually become one of the main forces of hypoglycemic drugs, and domestic pharmaceutical companies have stepped up the layout of class 1 new drugs
Time of Update: 2022-09-14
On August 25 this year, Hisco announced that it had completed two Phase 3 clinical trials of its new drug HSK7653 tablets and obtained preliminary statistical analysis results.
-
Recently, a number of new drugs have been included in the list of breakthrough treatment varieties
Time of Update: 2022-09-14
STSP-0601 for injection was included in the list of breakthrough therapeutic varieties On September 7, Shu Taishen announced that, according to the public information released by the Drug Evaluation Center (CDE) of the State Drug Administration, STSP-0601 for injection for bleeding in hemophilia A or B patients with inhibitors has been included in the list of breakthrough treatment varieties.
-
Since the beginning of this year, many pharmaceutical companies have been fined for environmental protection problems!
Time of Update: 2022-09-14
On February 9, 2022, Xinhua Pharmaceutical was fined 132,000 yuan by the Zibo Municipal Bureau of Ecology and Environment, and fined a total of 253,800 yuan for two environmental protection issues because it violated Article 18 of the Regulations on the Administration of Pollution Discharge Permits because the pollutant discharge methods and discharge destinations did not match the discharge permits.
-
The pharmaceutical industry is accelerating the "green" transformation, and pharmaceutical machinery companies need to seize the opportunity
Time of Update: 2022-09-14
It is worth noting that in the context of pharmaceutical companies accelerating the introduction of new environmental protection processes and new technologies, continuously improving environmental protection hardware supporting facilities, and building a clean, low-carbon and circular green manufacturing system, the industry believes that the pharmaceutical equipment industry will also usher in opportunities for accelerated development.
-
With the advancement of basic research, the ophthalmic market is gradually entering the era of innovative drugs
Time of Update: 2022-09-14
In July, Weiyan Bio announced that its self-developed innovative drug VVN539 (for the treatment of open-angle glaucoma) completed the enrollment of the first patient in the United States phase II clinical trial, marking that the development of the first independent innovation drug for glaucoma in China has entered a rapid stage of advancement.
-
13 pharmaceutical companies shortlisted in the 2022 China Top 500 Private Enterprises List!
Time of Update: 2022-09-14
Under the background that energy conservation and environmental protection have become a major theme of the manufacturing industry, most of the shortlisted private pharmaceutical companies have actively participated in the pollution prevention and control battle, and the number of participating enterprises has reached 12, accounting for 2.
-
449 pharmaceutical companies in the first half of the year report card released! 21 companies have revenues of more than 10 billion yuan
Time of Update: 2022-09-14
2 billion yuan, Mindray Medical has exceeded 5 billion yuan, and Renfu Pharmaceutical, Jichuan Pharmaceutical, Kai Laiying and so on have broken 1 billion yuan for the first time; From the perspective of revenue, 21 companies exceed the scale of 10 billion yuan, and Shanghai Pharmaceutical ranks first; From the perspective of gross profit margin, 12 companies such as Maiwei Biology, Shenzhou Cell, and Wuwu Biology exceed 90%.
-
Pharmaceutical companies borrow "boats" to go to sea into a trend! Blockbuster deals are frequent
Time of Update: 2022-09-14
In the context of fierce competition in the domestic pharmaceutical market, "license out" has become the main model of domestic pharmaceutical companies going to sea in recent years, this kind of adva
-
Domestic pharmaceutical companies are scrambling to lay out DPP-4 inhibitors, and the market pattern is about to change dramatically
Time of Update: 2022-09-14
Among them, DPP-4 inhibitors are new types of oral diabetes medications listed in recent years, and their status in the hypoglycemic industry is currently rising.
Among them, DPP-4 inhibitors are new types of oral diabetes medications listed in recent years, and their status in the hypoglycemic industry is currently rising.
-
Domestic innovative drugs have gradually entered the period of achievement exchange, and the competition in research and development of these popular tracks will intensify
Time of Update: 2022-09-14
It can be seen from the reports of many pharmaceutical companies that through continuous investment in research and development, a number of pharmaceutical companies have achieved great results in innovative drugs and made a considerable contribution to the growth of performance in the first half of the year.
-
Commercialization capability PK! Baekje, Innovent, Fuhong Henlin lead the way, Junshi's successor is weak? How does the unprofitable Biotech survive?
Time of Update: 2022-09-14
Industry insiders said that from Biotech to Biopharma transformation, innovative research and development capabilities are of course the "yardstick" to measure a biomedical company; At the same time, in the face of more and more arduous market tests, commercial capacity building has obviously become a competitiveness that cannot be ignored, and being able to obtain large-scale sales and stable profitability is also the core element of long-term development of enterprises.
-
The opportunity for import substitution is coming! Some pharmaceutical equipment companies plan to increase the proportion of international revenue to more than 50%.
Time of Update: 2022-09-14
Strive to surpass domestic revenue from overseas business around 2030 Judging from the progress of Chutian Technology's overseas business expansion, the company has gradually expanded from the cautious promotion in previous years to the vigorous expansion of overseas markets in the past two years, and has established sales and service centers in many countries and regions around the world.
-
National Health Commission: Strive to Solve the Problem of Medical Treatment for the Masses The medical reform has achieved remarkable results
Time of Update: 2022-09-14
The Propaganda Department of the CPC Central Committee held a press conference on the 7th to introduce the achievements in the development of health and health since the Eighteenth National Congress
-
Novartis, Pfizer and Hengrui all have more than 10 products competing for the 2022 medical insurance directory
Time of Update: 2022-09-14
In addition, Novartis Class 1 innovative drug Sinimod tablets also appeared on this year's preliminary review list of medical insurance negotiations.
In addition, Novartis Class 1 innovative drug Sinimod tablets also appeared on this year's preliminary review list of medical insurance negotiations.
-
Chinese medicine "going to sea" has made new achievements! The total export trade of related products exceeded 28 billion US dollars
Time of Update: 2022-09-14
In addition to the remarkable results in the total export trade of traditional Chinese medicine products, as of now, China has built 31 national traditional Chinese medicine service export bases, and the State Administration of Traditional Chinese Medicine has supported domestic traditional Chinese medicine institutions to build 30 high-quality overseas centers of traditional Chinese medicine in the "Belt and Road" countries and 56 international cooperation bases for traditional Chinese medicine in China.
